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Abstract 
The RET proto-oncogene encodes a receptor tyrosine kinase that is activated by glial cell derived 
neutrotrophic factor (GDNF). Previous studies have found that a single nucleotide polymorphism 
(SNP), RETp (G691S), in the juxtamembrane domain, enhances the signaling pathway and 
promotes tumor growth by GDNF in pancreatic and thyroid cancer in addition to melanoma. It is 
uncertain however whether this SNP is a germline variant or somatic mutation. A prior study 
reported that the RETp variant was a germline SNP in desmoplastic and non-desmoplastic 
melanomas. In the present study, we examined both melanoma tissue samples and matching 
peripheral blood DNA to determine if RETp was 1) a germline or somatic variant, 2) more 
frequent in certain melanoma subtypes, and 3) frequency in brain metastasis. We examined the 
peripheral blood of 197 melanoma patients who had at least one matched tumor, and 42 patients 
with brain metastasis. RETp was present as a germline SNP in 33% of patients. There were no 
significant differences in RETp frequency among the different melanoma subtypes, and RETp 
was not correlated with brain metastasis. 
Keywords  
 
RETp, G691S, melanoma, whole exome sequencing, germline variant 
 
Introduction 
 
Melanoma is a unique form of cancer because of the disparity in its prognosis. When caught 
early there is an excellent chance of survival. However, once metastasis has occurred survival 
rates drop significantly despite recent advances in current molecular targeted and immune 
therapies.1   The major cause of death remains brain metastasis.  In an early study by Amer et al. 
it was shown that patients with metastatic melanoma had a 75% likelihood of brain involvement 
found at autopsy.2  A recent large study of almost 700 patients diagnosed with melanoma brain 
metastases  found a mean survival time of less than 5 months.3  Melanoma metastasizing to the 
central nervous system is not unexpected considering that during development neural crest cells 
are the precursor cells for melanocytes, where melanoma originates.4 Additionally, one of the 
common findings in melanoma is neuronal tracking, and it has been suggested that this may be 
related to expression of the proto-oncogene RET.5 Plaza-Menacho et al. found that mutations 
that constitutively activated the RET receptor were highly related to cancers of the 
neuroendocrine system and of neural crest lineage.6 
 
RET (REarranged during Transfection), a proto-oncogene, encodes a receptor tyrosine kinase 
which is activated by a glial cell line-derived neurotrophic factor (GDNF). The receptor is 
anchored to the cell membrane by a glycosylphosphatidylinositol-anchored protein and is 
expressed by many cell types including melanocytes and melanoma cells.7,8 Interest in RET with 
regard to melanoma is relatively new, as it has historically been the focus of neuroendocrine 
related tumors. Deleterious mutations in RET have been shown to interact with other genes in 
Hirschsprungs disease, which affects the enteric nervous system, and in multiple endocrine 
neoplasia type II.9,10 Despite melanocytes being neural crest derived, there are very few studies 
linking the RET proto-oncogene to melanoma.  
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RETp (p.G691S) is located in the intracellular juxtamembrane domain encoded by exon 11, and 
may enhance the GDNF receptor-mediated cell proliferation and invasion.7  It is commonly 
found in patients with medullary carcinoma of the thyroid and pancreatic cancer, but also as a 
germline variant in normal individuals.7,11 Initial studies relating RETp to melanoma suggested 
that RETp was the result of a  somatic mutation and occurs in 31% of cutaneous melanomas 
while present in just 15% of the general population.12,13 This suggests that RETp places a 
pathogenic role in melanoma just as it does in other neuroendocrine tumors. In a subsequent 
melanoma study, Barr et al. showed that RETp is primarily a germline variant in desmoplastic 
melanoma and not a somatic mutation.14 This raised the question whether RETp can occur in 
melanoma as either a polymorphism or a somatic mutation similar to findings reported in 
pancreatic cancer.7 Moreover, it was also unclear as to whether this was unique to desmoplastic 
melanoma, or occurred in all histologic types of melanoma. To clarify these questions, we sought 
to determine if RETp is a germline variant in all melanoma subtypes, whether RETp is related to 
certain histologic subtypes of melanoma and whether there is a correlation with brain metastasis.  
 
Materials and Methods 
 
Sample Collection and genomic DNA isolation 
 
Both tissue and peripheral blood samples were collected from melanoma patients at the 
University of Colorado Cancer Center. Samples were the stored in the International Melanoma 
Biorepository and Research Laboratory (IMBRL) located on the University of Colorado 
Anschutz Medical Campus. All collection was done in accordance with institutional review 
board approval and with written informed consent (COMIRB-05-0309).   One hundred and 
ninety-seven melanoma patients with blood and tissue samples in the biorepository were 
examined.  Many of these patients had multiple tissue or peripheral blood samples collected at 
different times and all samples where adequate DNA could be extracted were used as data. 
Sample storage, preparation and DNA isolation was performed as previously described.13   
 
Whole Exome Sequencing (WES) Library Preparation and Sequencing 
 
DNA concentration and purity was determined using Qubit (Thermo Fisher Scientific) and 
Agilent 2100 bioanalzyer analysis. Genomic DNA (200 ng) was sheared using Covaris S220 at 
150bp. Sheared DNA was used to construct the exome library following Agilent SureSelect XT 
Target Enrichment System for Illumina Paired End Multiplexed Sequencing Library (cat# 
G9641B). Sheared DNA was end repaired followed by addition of adapter tags to construct DNA 
libraries through PCR amplification. Exome capture was done through hybridization using XT5 
probe. Resulting captured libraries were indexed and purified. The cDNA library was validated 
on the Agilent 2100 Bioanalzyer using DNA-1000 chip. Libraries were sequenced on the 
Illumina HiSeq 2000 with 125 bp paired-end reads. We obtained an average of 400X and 200X 
sequencing coverage for the cancer and normal exomes, respectively.  
 
WES and Polymerase Chain Reaction Analysis WES data analysis 
 
WES data from patients were analyzed using IMPACT, our recently published WES analysis 
pipeline.14   In brief, exome sequences were mapped to the human hg19 reference exome using 
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the Burrows-Wheeler Aligner (BWA) (v0.7.8-r455).16  SAMTools (v1.1)17 and BCFtools (v1.1) 
were utilized to generate a variant call format (VCF) file that was annotated by ANNOVAR 
(v2014-11-12).18  A minimum of 20 reads had to occur for a variant to be called.  Of those 20 
reads at least 4 reads needed to be mutated, or 10% of all reads needed to be mutated. From the 
VCF file, we compared the paired-normal and tumor samples to determine germline or somatic 
RETp variant. 
 
PCR Sequencing 
   
An additional 49 patient peripheral blood samples with desmoplastic melanoma that did not have 
matched tumor samples were analyzed with PCR and Direct Sanger Sequencing.  The methods 
used for PCR sequencing were previously described by Barr et al and were used to determine the 
RETp genotypes of samples that had not undergone WES.13  
 
The Cancer Genome Atlas (TCGA) Skin Cutaneous Melanoma Samples 
 
TCGA is a joint effort between the National Cancer Institute and the National Human Genome 
Research Institute to track genomic changes in many types of cancer.  In order to increase the 
power of the study, we obtained the germline and somatic variants of 331 cutaneous melanoma 
patients from the TCGA Data Portal (https://tcga-data.nci.nih.gov/).19   From the SNP variant 
call format (VCF), we extracted the RETp (rs1799939) from these patients. RETp variant from 
these patients were classified as germline or somatic based on the Broad Institute Automatic 
Mutation Analysis.  
  
Statistical analysis 
 
Genotypes of each sample were determined and a two-tailed Fisher’s exact test was done to 
determine differences between groups of samples. A hypergeometric test was performed to 
determine the difference between molecular subtypes.  P < 0.05 was considered as statistically 
significant. 
 
Results 
 
Whole exome sequencing of 197 melanoma patients across multiple subtypes was assessed by 
next-generation sequencing. On average, we obtained 400X coverage for cancer and 200X 
coverage for normal exomes. The mapping rate for these exomes was 94%. To evaluate whether 
RETp is a germline or somatic variant, we compared the paired normal and tumor exomes in 197 
melanoma patients. We found the RETp variant in 65 patients where 62 (95%) and 3 (5%) were 
germline and somatic variants, respectively (Figure 1A). Similarly, 107 of the 331 (32%) TCGA 
cutaneous melanoma patients carried this RETp variant. Among the 107 TCGA melanoma 
patients with RETp, 103 (96%) and 4 (4%) were germline and somatic variant, respectively 
(Figure 1B). From both data sets, we can conclude that RETp is a germline variant in melanoma. 
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Figure 1. RETp Proportion in IMBRL and TCGA. 
 
Proportion of patients with RETp variant (germline or somatic) and RETwt wildtype in IMBRL 
(a) and TCGA (b) datasets. 
 
To assess whether RETp is more frequent in certain melanoma subtypes, we evaluated the 
germline RETp variant across six melanoma subtypes in the peripheral blood of 197 WES 
patient’s and 49 desmoplastic patients (acral lentiginous, mucosal, nodular, superficial spreading, 
unknown primary, and desmoplastic).  We found that on average, 33% of the 246 patients carried 
a RETp germline variant (Table 1) in these subtypes, with range from 29 – 42%. In this study, 
we found that the nodular subtype had the highest percentage of the RETp germline variant 
(42%, p-value = 0.27) among the other subtypes. There were no significant differences between 
RETp and RETwt frequency in any of the melanoma subtypes. Similarly, there was no 
significant difference in the frequency of RETp between melanoma subtypes.  The RETp 
germline variant in our study is similar to the TCGA cutaneous melanoma samples (32%, 107 / 
331 RETp germline variant). This analysis strengthens the hypothesis that RETp is a germline 
variant in melanoma, and is not enriched in specific histological subtypes of melanoma.  
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  Table 1: Frequency of RETp germline across melanoma subtypes. 
Melanoma Subtype 
Wild-type 
RET 
RETp 
germline Total (% RETp) p-value 
Acral Lentiginous 9 5 14 (36) 0.7754 
Mucosal 9 4 13 (31) 1.0000 
Nodular 15 11 26 (42) 0.2739 
Superficial Spreading 43 17 60 (28) 0.5264 
Desmoplastic 36 19 55 (35) 0.7452 
Unknown Primary 8 5 13 (38) 0.7619 
Other 46 19 65 (29) 0.5408 
Total 166 80 246 (33) 
  
Next, we asked whether germline RETp is correlated with different molecular subtypes of 
melanoma in the cohort of 197 patients that were analyzed by WES. Here, we followed the four 
molecular subtypes of melanoma defined by: BRAF-mutant, NRAS-mutant, NF1-mutant and 
triple wild-type.19  In our 62 melanoma patient samples with germline RETp, 31%, 11%, 26% 
and 32% were BRAF-mutant, NRAS-mutant, NF1-mutant and triple wild-type subtypes, 
respectively (Figure 2a). Similarly, in the TCGA patients with the RETp germline variant there 
were 39%, 29%, 10%, and 22% RETp in the BRAF-mutant, NRAS-mutant, NF1-mutant and 
triple wild-type subtypes, respectively (Figure 2b).  A hypergeometric test concluded there was 
no enrichment of RETp in any of these molecular subtypes in either cohort (p-value > 0.5). S1 
Table lists out the distribution of the germline RETp variant in these molecular subtypes for our 
cohort and the TCGA cutaneous melanoma cohort.  
 
Figure 2:  Comparison of Molecular subtypes of germline RETp in IMBRL and TCGA. 
 
Molecular Subtypes of melanoma (BRAF-mutant, NRAS-mutant, NF1-mutant and triple wild-
type) with germline RETp in IMBRL (a) and TCGA (b) samples. 
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We next asked whether germline RETp is correlated with brain metastasis in melanoma. We 
assessed germline RETp variant of 42 brain metastasis and 90 other metastasis patients in this 
study. We found that germline RETp variant was present in 33% of melanoma patients with 
brain metastasis and 31% of patients with other metastasis (p = 0.84) (Table 2). Additionally, we 
assessed whether germline RETp variant is correlated with primary vs metastatic melanoma. We 
found no enrichment of germline RETp variant with primary vs. metastases in our cohort as well 
as the TCGA cutaneous melanoma cohort (Table 2).  
 
Table 2. Frequency of germline RETp variant in melanoma patients with brain and other 
metastasis. 
 
Brain Metastasis Other Metastasis p-value 
RET wildtype 28 62 
 
Germline RETp 14 28 
 
Total (% RETp) 42 (33) 90 (31) 0.84 
 
Discussion 
 
In this study, we performed a systematic analysis of RETp variant in melanoma using whole 
exome sequencing data. We demonstrated that RETp variant was found to be present in 33% of 
our 197 melanoma patients. This frequency is similar to the 331 TCGA cutaneous melanoma 
samples (32%). As one of our main objectives of this study was to determine whether RETp is a 
germline or a somatic variant, we assessed paired normal and matched melanoma patients in our 
data. We found that in 95% of the patients studied here RETp was germline, and this was 
supported by the same findings in TCGA cutaneous melanoma patients (96% of the RETp is 
germline variant). Based on these two large studies, we conclude that RETp is a germline variant 
in melanoma patients.  This also agrees with our previous study involving desmoplastic 
melanoma and RETp.14  This study is also an important example of why using both tumor and 
blood samples is essential to calling somatic variants.  Tumor-only analysis has the potential to 
incorrectly identify RETp as a somatic variant.  
  
To assess the frequency of germline RETp across melanoma subtypes, we evaluated this variant 
in acral lentiginous, mucosal, nodular, superficial spreading, unknown primary, and 
desmoplastic. From our data, we did not observe any association between germline RETp with 
melanoma subtypes.  In a limited number of available samples, acral melanomas had a higher 
incidence of the RETp variant. This subtype arises on glabrous skin which may account for the 
differences seen, however more samples are needed.   Similarly, we did not find any association 
of germline RETp with molecular subtypes of melanoma. 
 
Cutaneous melanoma can be classified into one of four molecular classifications based on the 
presence of hotspot mutations in BRAF or NRAS, deleterious mutations in NF1, or a lack of 
mutations in these three genes (triple wild type).18   We analyzed the presence of the RETp 
germline variant in each molecular classification for both cohorts of samples.  There was no 
enrichment of RETp in any of the four molecular classifications in either cohort of samples 
(Table 1).   
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To evaluate whether germline RETp is correlated with brain metastasis, we compared 42 brain 
metastasis and 90 samples from other metastatic sites. The percentage of germline RETp variant 
is 33% and 31% in brain metastasis and other metastasis, respectively. We did not find that brain 
metastasis is enriched for germline RETp. We also evaluated the presence of RETp in primary 
and metastatic sites in our cohort as well as the TCGA samples.  We found no association 
between the presence of RETp and primary or metastatic sites in either cohort (Table 2).   
 
In one of the studies done here, there was discordance between the blood and tumor tissue for 
RETp. There are multiple explanations for these findings including allelic loss and perhaps 
somatic mutation in tumor. These variants were not associated with any clinical scenario or other 
molecular events and have not been pursued further at this point.  
 
Despite the findings here multiple studies have shown the importance of alteration of RET in 
other cancers, particularly medullary and papillary carcinoma of the thyroid.20  In these cancers, 
rearrangements, point mutations, deletions and insertions have been demonstrated which may 
occur as both hereditary and somatic changes. While it was initially thought that many of these 
were exclusive to thyroid cancers, similar alterations have been then described in other cancers, 
but not malignant melanoma. We think that further studies in melanoma will however turn up 
similar activating alterations in RET and these are currently underway in our laboratory.  
 
 
Conclusion 
 
In summary, we have performed a systematic analysis of RETp variant in a large cohort of 
melanoma patients. By assessing the whole exome sequencing of these melanoma patients, we 
identified 33% and 32% of patient samples had RETp variants in our samples and TCGA 
cutaneous melanomas, respectively. On average, 96% of the RETp variant is germline in our 
samples and TCGA samples. There was no association of germline RETp with melanoma 
subtypes and molecular subtypes. Furthermore, we did not find any enrichment of germline 
RETp in brain metastasis melanoma patients.  
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